C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis

Archives of Surgery

Volumn 142, Issue 11, 2007, Pages 1066-1071

  Mullenix, Philip S ^a   Steele, Scott R ^a   Martin, Matthew J ^a   Starnes, Benjamin W ^a   Andersen, Charles A ^a  

^a MADIGAN ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PREDICTION; PRIORITY JOURNAL; RISK FACTOR;

AGED; C-REACTIVE PROTEIN; CAROTID STENOSIS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; VASCULAR DISEASES;

EID: 36348965977     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.142.11.1066     Document Type: Article

References (29)

1. Ridker PM, Cushman M, Stampher MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336(14):973-979.
2. Koenig W, Sund M, Fröhlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99(2):237-242.
3. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499-511.
4. Ridker PM, Rafai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557-1565.
5. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285(19):2481-2485.
6. Rost NS, Wolf PA, Case CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham Study. Stroke. 2001;32(11):2575-2579.
7. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004;109(25)(suppl 1):IV6-IV19.
8. Fletcher RH, Fletcher SW, Wagner EH. Clinical Epidemiology: The Essentials. 3rd ed. Baltimore, MD: Williams & Wilkins; 1996.
9. Moneta GL, Edwards JM, Papnicolaou G, et al. Screening for asymptomatic internal carotid artery stenosis: duplex criteria for discriminating 60% to 99% stenosis. J Vasc Surg. 1995;21(6):989-994.
10. Carpenter JP, Lexa FJ, Davis JT. Determination of sixty percent or greater carotid artery stenosis by duplex Doppler ultrasonography. J Vasc Surg. 1995;22(6):697-705.
11. Lumley T, Diehr P, Emerson S, Chen L. The importance of the normality assumption in large public health data sets [published online ahead of print October 25, 2001]. Annu Rev Public Health. 2002;23:151-169.doi:10.1146/ annurev.publhealth.23.100901.140546.
12. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology. 1995;6(4):356-365.
13. Mullenix PS, Steele SR, Martin MJ, Starnes BW, Andersen CA. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of carotid stenosis. J Am Coll Surg. 2004;194(3S).
14. Zukowski AJ, Nicolaides AN, Lewis RT, et al. The correlation between carotid plaque ulceration and cerebral infarction seen on CT scan [abstract]. J Vasc Surg. 1984;1(6):782-786.
15. Alvarez Garcia B, Ruiz C, Chacon P, Sabin JA, Matas M. High-sensitivity C-reactive protein in high-grade carotid stenosis: risk marker for unstable carotid plaque. J Vasc Surg. 2003;38(5):1018-1024.
16. Wang TJ, Nam BH, Wilson PW, et al. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2002;22(10):1662-1667.
17. Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke. 2001;32(1):133-138.
18. Canova CR, Courtin C, Reinhart WH. C-reactive protein (CRP) in cerebrovascular events. Atherosclerosis. 1999;147(1):49-53.
19. Rerkasem K, Shearman CP, Williams JA, et al. C-reactive protein is elevated in symptomatic compared with asymptomatic patients with carotid artery disease. Eur J Vasc Endovasc Surg. 2002;23(6):505-509.
20. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA. 1995;273(18):1421-1428.
21. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325(7):445-453.
22. Schönbeck U, Libby P. Inflammation, immunity and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation. 2004;109(21)(suppl 1):II18-II26.
23. Viedt C, Shen W, Fei J, et al. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9 [published online ahead of print September 22, 2003]. Basic Res Cardiol. 2003;98(6):353-361. doi:10.1007/s00395-003-0437-4.
24. Shishehbor MH, Aviles RJ, Brennan ML, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA. 2003;289(13):1675-1680.
25. Martín-Ventura JL, Ortego M, Esbrit P, Hernández-Presa MA, Ortega L, Egido J. Possible role of parathyroid hormone-related protein as a proinflammatory cytokine in atherosclerosis [published online ahead of print June 12, 2003]. Stroke. 2003;34(7):1783-1789. doi:10.1161/01.STR. 0000078371.00577.76.
26. Shapiro M, Hanon S, Misra D. Drug-eluting stents. Hosp Phys. 2004;12:11-20.
27. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis [editorial]. Circulation. 2001;104(8):852-855.
28. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773-1780.
29. Serruys PW, Degertekin M, Tanabe K, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (Randomized Study With the Sirolimus-Eluting Velocity Balloon-Expandable Stents in the Treatment of Patients With de novo Native Coronary Artery Lesions) trial. Circulation. 2002; 106(7):798-803.